Clinical Trial Update: Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study [Phase 1]

View source ↗

Summary

Phase 1, single-arm study evaluating trifluridine/tipiracil (TAS-102) in combination with bevacizumab and putalimab for metastatic colorectal cancer after cytor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Putalimab (putalimab)
• TAS-102 (trifluridine/tipiracil) (trifluridine/tipiracil)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Colorectal Cancer (CRC) | Phase 1 | Status: NOT_YET_RECRUITING